Research monograph · modified grf(1-29), protease-resistant synthetic ghrh(1-29) analog (no albumin-binding dac)
GH Half-Life Studies
This monograph collects what the published literature reports about CJC-1295 — its mechanisms, the areas it is studied in, its molecular record and the sources behind them. Each substitution targets a site where enzymes would otherwise cleave the sequence, extending how long the molecule survives in circulation compared with unmodified GHRH. Research measures growth hormone release profiles and the shape of the resulting pulse.
For laboratory research use only — not for human or animal use
Mechanisms
GHRH Receptor Activation
Four substitutions — at positions 2, 8, 15 and 27 — each block a site where enzymes would cleave native GHRH(1-29). The receptor interaction is unchanged; only the molecule's survival time is.
Pulsatile GH Secretion
A roughly thirty-minute half-life produces discrete pulses rather than the sustained elevation the DAC variant gives. That difference is the reason both versions exist and are studied separately.
GH/IGF-1 Axis Stimulation
Each pulse drives a transient rise in hepatic IGF-1. Because exposure is brief, the IGF-1 profile differs markedly from the prolonged elevation reported with the DAC variant.
Studied applications
The short half-life is the feature here: it produces discrete pulses, which is what makes the compound useful for studying release pattern rather than total exposure.
Teichman et al. 2006
Most often studied head-to-head against the DAC variant, where the only meaningful variable is duration of action.
Frohman et al. 2003
Combination work pairs it with a ghrelin-receptor agonist to test whether engaging two receptor populations amplifies the pulse.
Raun et al. 1998
Animal models examine whether upstream stimulation restores a release pattern closer to normal physiology than exogenous growth hormone does.
Alba et al. 2006
What the published work measures
The endpoints reported across the literature for this compound. The figures belong to the individual papers, not to us.
Reference values
Scroll for full molecular data →
| Molecular weight | 3,367.97 g/mol |
|---|---|
| Molecular formula | C152H252N44O42 |
| Physical form | Lyophilized Powder |
| Documented purity | Quantified by HPLC, reported per lot |
| Storage | -20°C for up to 24 months |
| Solubility | Water-soluble |
| Available sizes | 5mg |
FAQ
CJC-1295 without DAC is a modified GHRH fragment carrying four amino acid substitutions. Each substitution targets a site where enzymes would otherwise cleave the sequence, extending how long the molecule survives in circulation compared with unmodified GHRH. Research measures growth hormone release profiles and the shape of the resulting pulse.
Published research on CJC-1295 concentrates on Pulsatile GH Research, GHRH Analog Comparison, CJC / Ipamorelin Synergy and GHRH Axis Restoration. Each of those areas is summarised further up this page with the citation it comes from, and the full reference list — 4 indexed publications — sits at the bottom. Study designs and concentrations vary considerably between publications, so the primary sources are worth reading directly.
The literature describes CJC-1295 acting across GHRH Receptor Activation, Pulsatile GH Secretion and GH/IGF-1 Axis Stimulation, reported respectively as GHRH-R Agonist, Pulsatile GH and IGF-1 Axis. Those pathways are drawn from preclinical models rather than clinical work, and they describe what has been observed rather than a settled mechanism — the individual pathway cards above cite what each one is based on.
CJC-1295 has a molecular formula of C152H252N44O42 and an average mass of 3367.97 g/mol. It is indexed under CAS 863288-34-0. It ships as lyophilized powder. Those are nominal reference values for the parent compound. The identity of the specific material you receive is confirmed by mass spectrometry and reported on that lot's certificate.
Store the sealed vial at -20°C, protected from light and moisture, and let it reach room temperature before opening so condensation does not form on cold powder. CJC-1295 is water-soluble; reconstitute by directing the diluent down the vial wall rather than onto the powder, then swirl to dissolve rather than shaking. Keep reconstituted solution refrigerated and avoid repeated freeze-thaw cycles — solutions are far less stable than lyophilized powder.
No. CJC-1295 is supplied strictly for in-vitro laboratory research and development. It is not a drug, food, supplement or cosmetic, it has not been evaluated by the FDA, and it is not intended for human or animal consumption, ingestion, injection or any in-vivo use. Ordering confirms you are a qualified researcher or institution purchasing on that basis.
Cited sources
Independent published research indexed from PubMed — not Routine Peptides claims.
Before you order
Every production run is analyzed by an independent laboratory, and the certificate for your lot travels with the order — not a catalog-wide document, and not a summary written by us.
